SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

PubWeight™: 3.29‹?› | Rank: Top 1%

🔗 View Article (PMID 32142651)

Published in Cell on March 05, 2020

Authors

Markus Hoffmann1, Hannah Kleine-Weber2, Simon Schroeder3, Nadine Krüger4, Tanja Herrler5, Sandra Erichsen6, Tobias S Schiergens7, Georg Herrler8, Nai-Huei Wu8, Andreas Nitsche9, Marcel A Müller10, Christian Drosten3, Stefan Pöhlmann11

Author Affiliations

1: Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany. Electronic address: mhoffmann@dpz.eu.
2: Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany; Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany.
3: Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany; German Centre for Infection Research, associated partner Charité, Berlin, Germany.
4: Institute of Virology, University of Veterinary Medicine Hannover, Hannover, Germany; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.
5: BG Unfallklinik Murnau, Murnau, Germany.
6: Institute for Biomechanics, BG Unfallklinik Murnau, Murnau, Germany; Institute for Biomechanics, Paracelsus Medical University Salzburg, Salzburg, Austria.
7: Biobank of the Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany.
8: Institute of Virology, University of Veterinary Medicine Hannover, Hannover, Germany.
9: Robert Koch Institute, ZBS 1 Highly Pathogenic Viruses, WHO Collaborating Centre for Emerging Infections and Biological Threats, Berlin, Germany.
10: Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany; German Centre for Infection Research, associated partner Charité, Berlin, Germany; Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov University, Moscow, Russia.
11: Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany; Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany. Electronic address: spoehlmann@dpz.eu.

Associated clinical trials:

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (REPLACECOVID) | NCT04338009

CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 (CORONA) | NCT04378244

Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health. (COVID-19) | NCT04388631

NO-mediated Vascular Function in Covid-19 Patient | NCT04625036

Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19). (APEL-COVID) | NCT04632732

Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2) (BeeCovid2) | NCT04800224

Phase II Immunogenicity Study of AVX/COVID-12 (Patria) Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence | NCT05205746